Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 11/20 | 0.48 |
| ▸ | F2 | P00734 | 10/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.45 |
| ▸ | FPR2 | P25090 | 2/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.44 |
| ▸ | MAT2A | P31153 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3347621 | 0.78 | ELANE (0.54) | SCN9AMAT2ADPP4ELANE | |
| SCHEMBL2172636 | 0.78 | ELANE (0.54) | SCN9AMAT2ADPP4ELANE | |
| SCHEMBL15665470 | 0.78 | ELANE (0.54) | SCN9AMAT2ADPP4ELANE | |
| Hydrochloric Acid SCHEMBL27002674 | 0.77 | ELANE (0.53) | SCN9AMAT2ADPP4ELANE | |
| Trifluoroacetic Acid SCHEMBL30850139 | 0.76 | SCN9A (0.43) | F10FPR2SCN9ADPP4DPP8 | |
| Hydrochloric Acid SCHEMBL14632606 | 0.75 | F10 (0.50) | F10F2PRSS1 | |
| Hydrochloric Acid SCHEMBL14632425 | 0.75 | F10 (0.50) | F10F2PRSS1 | |
| SCHEMBL7497512 | 0.74 | ELANE (0.50) | SCN9AMAT2ADPP4ELANE | |
| SCHEMBL27534007 | 0.74 | ELANE (0.50) | SCN9AMAT2ADPP4ELANE | |
| Trifluoroacetic Acid SCHEMBL10277408 | 0.73 | PARP1 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486278-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2025-12-02 | — | — | US | disclosed |
| US-20240092788-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2024-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486278-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | F10 4184/4885F2 4221/4885PRSS1 159/4885 |
| US-20240092788-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | F10 4184/4885F2 4221/4885PRSS1 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.